The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 376, Issue 4, 2007, Pages 285-293

  Kracke, George R ^a   Stoneking, Sean P ^a   Ball, Joshua M ^a   Tilghman, Brandon M ^a   Washington, Carmen C ^a   Hotaling, Katherine A ^a   Johnson, Joel O ^a   Tobias, Joseph D ^a  

^a University of Missouri   (United States)

Author keywords

Anandamide; Cannabinoids; DAMGO; Mu opioid receptor; Pain; Potassium channel; WIN 55,212 2; Xenopus oocytes

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE;

ARTICLE; CONTROLLED STUDY; FEMALE; NONHUMAN; OOCYTE; POTASSIUM CURRENT; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; VOLTAGE CLAMP; XENOPUS LAEVIS;

ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; CANNABINOIDS; CLONING, MOLECULAR; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; MICE; MORPHOLINES; NAPHTHALENES; OOCYTES; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; XENOPUS LAEVIS;

EID: 36448987528     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0201-7     Document Type: Article

References (43)

1. Akinshola BE, Taylor RE, Ogunseitan AB, Onaivi ES (1999) Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn-Schmiedeberg's Arch Pharmacol 360:242-248
2. 9-THC induced Fos expression in rat brain. Neuropharmacology 44:264-274
3. 9-tetrahydrocannabinol. Psychopharmacology 163:111-117
4. Bloom AS, Dewey WL, Harris LS, Brosius KK (1977) 9-nor-9β- hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine. J Pharmacol Exp Ther 200:263-270
5. Chapman V, Dickenson AH (2002) Pharmacologic plasticity associated with neuropathic pain states. In: Malmberg AB, Chaplan SR (eds) Mechanisms and mediators of neuropathic pain. Birkhäuser, Basel, pp 79-87
6. Coda B, Bausch S, Hass M, Chavkin C (1997) The hypothesis that antagonism of fentanyl analgesia by 2-chloroprocaine is mediated by direct action on opioid receptors. Reg Anesth 22:43-52
7. Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38:44-48
8. Demuth DG, Molleman A (2006) Cannabinoid signalling. Life Sci 78:549-563
9. Fisyunov A, Tsintsadze V, Min R, Burnashev N, Lozovaya N (2006) Cannabinoids modulate the P-type high-voltage-activated calcium currents in Purkinje neurons. J Neurophysiol 96:1267-1277
10. Gray JA, Roth BL (2002) A last GASP for GPCRs? Science 297:529-531
11. Henry DJ, Chavkin C (1995) Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett 186:91-94
12. Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997) The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221:157-160
13. Hirota K, Lambert DG (1996) Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 77:441-444
14. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102:3093-3098
15. Iversen L, Chapman V (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2:50-55
16. Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Arch Pharmacol 372:354-361
17. Kracke GR, Stoneking SP, Ball JM, Tilghman BM, Tobias JD, Johnson JO (2006) The effect of the cannabinoids, anandamide and WIN 55,212-2, on mu opioid receptors expressed in Xenopus oocytes. International Anesthesia Research Society Annual Meeting. Abstract S-211
18. Kumar RN, Chambers WA, Pertwee RG (2001) Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 56:1059-1068
19. Manzanares J, Corchero J, Fuentes JA (1999a) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 839:173-179
20. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA (1999b) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20:287-294
21. Mason DJ, Lowe J, Welch SP (1999) Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur J Pharmacol 378:237-248
22. McAllister SD, Griffen G, Satin LS, Abood ME (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. J Pharmacol Exp Ther 291:618-626
23. Navarro M, Carrera MRA, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, Del Arco I, Villanua MA, Koob GF, Rodriguez de Fonseca F (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21:5344-5350
24. Niederhoffer N, Schmid K, Szabo B (2003) The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn-Schmiedeberg's Arch Pharmacol 367:434-443
25. Oye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209-1213
26. Pert CB, Snyder SH (1974) Opiate receptor binding of agonists and antagonists affected differentially by sodium. Mol Pharmacol 10:868-879
27. Pugh G, Abood ME, Welch SP (1995) Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord. Brain Res 684:157-158
28. Quasha AL, Eger EI, Tinker JH (1980) Determination and applications of MAC. Anesthesiology 55:315-334
29. Quick MW, Lester HA (1994) Methods of expression of excitability proteins in Xenopus oocytes. In: Narahashi T (ed) Methods in neuroscience-ion channels of excitable cells, vol 19. Academic, San Diego, pp 261-279
30. Rios C, Gomes I, Devi LA (2006) μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387-395
31. Rodriguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21:823-833
32. Schoffelmeer ANM, Hogenboom F, Wardeh G, De Vries TJ (2006) Interactions between CB1 cannabinoid and μ opioid receptors mediating inhibition of neurotransmitter release in rat nucleur accumbens core. Neuropharmacology 51:773-781
33. Smith FL, Fujimori K, Welch SP (1998) Characterization of delta 9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 60:183-191
34. 1 opioid receptor mechanism. Science 276:2048-2050
35. Thorat SN, Bhargava HN (1994) Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 260:5-13
36. Tulunay FC, Ayhan IH, Portoghese PS, Takemori AE (1981) Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. Eur J Pharmacol 70:219-224
37. 1 receptor antagonist, SR 141716. Eur J Pharmacol 445:55-59
38. Vaysse PJJ, Gardner EL, Zukin RS (1987) Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther 241:534-539
39. Vigano D, Rubino T, Parolaro (2005) Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 81:360-368
40. Williams CM, Kirkham TC (2002) Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71:333-340
41. 9-tetrahydrocannabinol. Eur J Pharmacol 539:57-63
42. Wilson RS, May EL (1975) Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J Med Chem 18:700-703
43. Zhang L, Yu Y, Mackin S, Weight FF, Uhl GR, Wang JB (1996) Differential μ opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem 271:11449-11454